138 related articles for article (PubMed ID: 2111742)
1. Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation.
Brenner B; Francis CW; Totterman S; Kessler CM; Rao AK; Rubin R; Kwaan HC; Gabriel KR; Marder VJ
Circulation; 1990 Jun; 81(6):1818-25. PubMed ID: 2111742
[TBL] [Abstract][Full Text] [Related]
2. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
3. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
Lawler CM; Bovill EG; Stump DC; Collen DJ; Mann KG; Tracy RP
Blood; 1990 Oct; 76(7):1341-8. PubMed ID: 2119827
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of plasma D-dimer in the diagnosis and in the course of fibrinolytic therapy of deep vein thrombosis and pulmonary embolism.
Knecht MF; Heinrich F; Spanuth E
Thromb Res; 1992 Jul; 67(2):213-20. PubMed ID: 1440523
[TBL] [Abstract][Full Text] [Related]
5. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA.
Eisenberg PR; Rylatt DB; Rusticali F; Ferrini D; Ottani F; Galvani M
Blood Coagul Fibrinolysis; 1997 Mar; 8(2):105-13. PubMed ID: 9518041
[TBL] [Abstract][Full Text] [Related]
6. The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction.
Brügger-Andersen T; Hetland Ø; Pönitz V; Grundt H; Nilsen DW
Thromb Res; 2007; 119(4):415-21. PubMed ID: 16650886
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the fibrinolytic system components during acute myocardial infarction.
Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
[TBL] [Abstract][Full Text] [Related]
8. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
Francis CW; Connaghan DG; Marder VJ
Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the thrombolytic effect of tissue-type plasminogen activator with ultrasonic irradiation: in vitro experiment involving assay of the fibrin degradation products from the clot.
Kimura M; Iijima S; Kobayashi K; Furuhata H
Biol Pharm Bull; 1994 Jan; 17(1):126-30. PubMed ID: 8148800
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma.
Koppert PW; Hoegee-de Nobel E; Nieuwenhuizen W
Thromb Haemost; 1988 Apr; 59(2):310-5. PubMed ID: 3133813
[TBL] [Abstract][Full Text] [Related]
12. Reactivity of D-dimer assays with the fibrinogen--fibrin split products generated by thrombolytic agents.
Amiral J; Minard F; Plassart V; Vissac AM; Chambrette B
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):525-30. PubMed ID: 2133230
[TBL] [Abstract][Full Text] [Related]
13. Laboratory assays and duplex scanning outcomes after symptomatic deep vein thrombosis: preliminary results.
Arcelus JI; Caprini JA; Hoffman KN; Fink N; Size GP; Fareed J; Hoppensteadt D
J Vasc Surg; 1996 Apr; 23(4):616-21. PubMed ID: 8627897
[TBL] [Abstract][Full Text] [Related]
14. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system.
Eisenberg PR; Sobel BE; Jaffe AS
Circulation; 1988 Sep; 78(3):592-7. PubMed ID: 3136954
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of D-dimer: evaluation during fibrinolytic treatment of venous thrombosis or myocardial infarction.
Simank HG; Simon M; Bode C; Zimmermann R; Kübler W; Weber E
Thromb Res; 1989 Nov; 56(4):541-6. PubMed ID: 2609291
[No Abstract] [Full Text] [Related]
17. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum D dimer: a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction.
Lew AS; Berberian L; Cercek B; Lee S; Shah PK; Ganz W
J Am Coll Cardiol; 1986 Jun; 7(6):1320-4. PubMed ID: 3711489
[TBL] [Abstract][Full Text] [Related]
19. Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction.
Soria J; Soria C; Mirshahi M; Xi M; Mirshahi M; Samama MM; Caen JP
Semin Thromb Hemost; 1987 Apr; 13(2):223-7. PubMed ID: 3114888
[TBL] [Abstract][Full Text] [Related]
20. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
